Evidence map›Paper›PMID 31437649›Full record

ReviewRespiratory medicine2019

Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV

Daniel Hoesterey, Nilakash Das, Wim Janssens, Russell G Buhr, Fernando J Martinez, Christopher B Cooper, Donald P Tashkin, Igor Barjaktarevic

Open access · bronzeAbstract readReview
In one paragraph

Review in Respiratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Early dysanapsis in experimental bronchopulmonary dysplasia: implications for lifelong lung disease.American journal of physiology. Lung cellular and molecular physiology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Reduced FEVInternational journal of chronic obstructive pulmonary disease · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Daniel HoestereyDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.
Nilakash DasLaboratory of Respiratory Diseases, Department of Chronic Diseases, Metabolism and Ageing, Katholieke Universiteit Leuven, Leuven, Belgium.
Wim JanssensLaboratory of Respiratory Diseases, Department of Chronic Diseases, Metabolism and Ageing, Katholieke Universiteit Leuven, Leuven, Belgium.
Russell G BuhrDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA; Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, USA; Medical Service, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, USA.
Fernando J MartinezDepartment of Medicine, Weill Cornell Medical College, USA.
Christopher B CooperDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA; Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, USA.
Donald P TashkinDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.
Igor BarjaktarevicDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA. Electronic address: ibarjaktarevic@mednet.ucla.edu.
University of California, Los Angeles · USKU Leuven · BECornell University · US

Funding

NRSA Training CoreTL1TR001883 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI, Nina Thawata Harawa · 2016 to 2026
$8.6M
NCATS NIH HHS TL1 TR001883NHLBI NIH HHS L30 HL134025
6 · The paper itself

Abstract

Spirometry is the current gold standard for diagnosing and monitoring the progression of Chronic Obstructive Pulmonary Disease (COPD). However, many current and former smokers who do not meet established spirometric criteria for the diagnosis of this disease have symptoms and clinical courses similar to those with diagnosed COPD. Large longitudinal observational studies following individuals at risk of developing COPD offer us additional insight into spirometric patterns of disease development and progression. Analysis of forced expiratory maneuver changes over time may allow us to better understand early changes predictive of progressive disease. This review discusses the theoretical ability of spirometry to capture fine pathophysiologic changes in early airway disease, highlights the shortcomings of current diagnostic criteria, and reviews existing evidence for spirometric measures which may be used to better detect early airflow impairment.

Indexed as

Forced Expiratory VolumeSpirometryVital CapacityPulmonary Disease, Chronic ObstructiveRiskEarly COPDObstructionSpirometry

Identifiers

PMID31437649
PMCPMC6768077
OpenAlexW2967655490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.